Pfizer Inc. (NYSE:PFE) Shares Bought by Commonwealth Financial Services LLC

Commonwealth Financial Services LLC boosted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 139.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 35,063 shares of the biopharmaceutical company’s stock after purchasing an additional 20,421 shares during the period. Commonwealth Financial Services LLC’s holdings in Pfizer were worth $930,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in PFE. Quarry LP acquired a new stake in shares of Pfizer during the second quarter valued at approximately $31,000. Czech National Bank increased its stake in Pfizer by 6.9% in the 3rd quarter. Czech National Bank now owns 1,154,366 shares of the biopharmaceutical company’s stock valued at $33,407,000 after buying an additional 74,737 shares during the period. GAMMA Investing LLC increased its stake in Pfizer by 48.9% in the 3rd quarter. GAMMA Investing LLC now owns 39,904 shares of the biopharmaceutical company’s stock valued at $1,155,000 after buying an additional 13,097 shares during the period. Diversified Trust Co increased its stake in Pfizer by 33.8% in the 3rd quarter. Diversified Trust Co now owns 113,505 shares of the biopharmaceutical company’s stock valued at $3,285,000 after buying an additional 28,658 shares during the period. Finally, Smith Anglin Financial LLC increased its stake in Pfizer by 2.2% in the 3rd quarter. Smith Anglin Financial LLC now owns 22,521 shares of the biopharmaceutical company’s stock valued at $652,000 after buying an additional 495 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on PFE shares. Guggenheim dropped their price objective on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. UBS Group dropped their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. Bank of America restated a “neutral” rating and set a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. Sanford C. Bernstein began coverage on shares of Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price objective for the company. Finally, Truist Financial decreased their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Trading Down 1.1 %

Shares of Pfizer stock opened at $26.23 on Tuesday. The stock has a market capitalization of $148.62 billion, a P/E ratio of 35.44, a price-to-earnings-growth ratio of 0.66 and a beta of 0.64. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The company has a 50-day simple moving average of $26.27 and a 200 day simple moving average of $27.85. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. Research analysts expect that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.56%. The ex-dividend date of this dividend is Friday, January 24th. This is a boost from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is presently 232.44%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.